Four in every 10 cancer patients treated with chemotherapy develop severe peripheral nerve pain, a new review suggests.

The pooled prevalence of chronic painful neuropathy is 41.22 percent among individuals with chemotherapy-induced peripheral neuropathy.

Pelareorep plus chemotherapy with or without Tecentriq had an acceptable safety profile in patients with newly diagnosed ...

But sometimes life throws us curveballs, like a major health issue. It's no fun to navigate treatment for cancer or other ...

SAN ANTONIO — Texas Oncology – San Antonio teamed up with Angeles Sin Fronteras to provide free wigs and cosmetic kits to ...

The shortage of generic chemotherapy drugs cisplatin and carboplatin that began in early 2023 did not increase short-term ...

Among older adults with classical Hodgkin lymphoma, frontline N-AVD has been found to be highly effective and well-tolerated.

Managing maximum tolerated dose (MTD) chemotherapy while minimizing neutropenia relies on precise complete blood count (CBC) monitoring and AI-powered diagnostics.

Among patients with chemotherapy-induced peripheral neuropathy, those treated with platinum-based agents, taxanes had highest prevalence. (HealthDay News) — The pooled prevalence of chronic ...

Four in every 10 cancer patients treated with chemotherapy develop severe peripheral nerve pain, a new evidence review suggests. These patients might experience loss of balance and coordination ...

Love, sweet and woman with her mom with cancer hugging, bonding and spending time together. Recovery, chemotherapy and sick mature female person embracing her adult daughter in an outdoor garden ...